Kong Qing-You, Liu Jia, Chen Xiao-Yan, Wang Xiao-Wei, Sun Yuan, Li Hong
Cancer Institute and Laboratory of Cell Biology and Molecular Genetics, College of Basic Medical Sciences, Dalian Medical University, PR China.
Oncol Rep. 2003 Jan-Feb;10(1):51-5.
Recurrence due to invasive growth is the major risk factor of transitional cell carcinoma (TCC) of urinary bladder. The interactions of hyaluronic acid (HA) and its receptors, CD44 and RHAMM, on cancer cells can promote invasion and metastasis but parallel study on these two genes in TCCs has not been available. The current work is aimed to address this issue by frozen tissue array-based immunocytochemical staining and Western blot hybridization. The results revealed that 19 out of 28 non-cancerous mucosa (68%) expressed CD44, in which 9 (33%) harbored variant exon 6 (v6). CD44 and v6 were both 5/11 (46%) in papillary, non-invasive carcinomas (pTa) and 6/14 (43%) in the tumors remained in sub-epithelial layer (pT1), while 5/29 (17%) and 3/29 (10%) in pT2-4 invasive tumors. RHAMM expression was uncommon in non-cancerous mucosa (5/28) but became frequent in pTa (9/11), pT1 (12/14) and pT2-4 (24/29) tumors. RHAMM proteins were labeled intracellularly and showed more than one isoforms. Our data further confirm the promising prognostic value of CD44 for TCC patients and demonstrate, for the first time, the correlation between RHAMM expression and malignant transformation of urothelial cells.
浸润性生长导致的复发是膀胱移行细胞癌(TCC)的主要危险因素。癌细胞上透明质酸(HA)及其受体CD44和RHAMM之间的相互作用可促进侵袭和转移,但尚未有对TCC中这两个基因的平行研究。当前工作旨在通过基于冷冻组织芯片的免疫细胞化学染色和蛋白质印迹杂交来解决这一问题。结果显示,28例非癌黏膜中有19例(68%)表达CD44,其中9例(33%)含有可变外显子6(v6)。在乳头状非浸润性癌(pTa)中,CD44和v6的表达率均为5/11(46%),在仍局限于上皮下层的肿瘤(pT1)中为6/14(43%),而在pT2 - 4浸润性肿瘤中分别为5/29(17%)和3/29(10%)。RHAMM在非癌黏膜中表达罕见(5/28),但在pTa(9/11)、pT1(12/14)和pT2 - 4(24/29)肿瘤中表达频率增加。RHAMM蛋白在细胞内标记,且显示出不止一种异构体。我们的数据进一步证实了CD44对TCC患者有良好的预后价值,并首次证明了RHAMM表达与尿路上皮细胞恶性转化之间的相关性。